Skip to main content
Rayyan Syed Kamal on Muck Rack

Rayyan Syed Kamal

As seen in: Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Rayyan Syed

Contact Rayyan Syed, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Hypoglycemia as first presentation of presumed immune checkpoint inhibitor‐induced type 1 diabetes

|
By Rayyan Syed Kamal, Arleigh Dean, Hanna Dutt, Adnan Rajeh
| Wiley Online Library Verified
1 INTRODUCTION Immunotherapy has been a trending development in the treatment of advanced cancers. While cancers may promote immune tolerance and inhibition, immune checkpoint inhibitors (ICIs) help sustain the patient's anti-tumor immune response. Monoclonal antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4) (ipilimumab) and programmed death protein 1 (PD-1) (nivolumab) are ICIs commonly used in combination for the treatment of metastatic cancer.
Open in Who Shared Issue with article?
See all 1 articles